Interferon-gamma-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C

Archive ouverte

Dill, M | Makowska, Z | Duong, F | Merkofer, F | Filipowicz, M | Baumert, Thomas | Tornillo, L | Terracciano, L | Heim, M

Edité par CCSD ; Elsevier -

BACKGROUND & AIMS: Approximately 50% of patients with chronic hepatitis C (CHC) have a sustained virologic response to treatment with pegylated interferon (pegIFN)-alpha and ribavirin. Nonresponse to treatment is associated with constitutively increased expression of IFN-stimulated genes (ISGs) in the liver. Treatment of patients with acute hepatitis C (AHC) is more effective, with sustained virologic response rates greater than 90%. We investigated mechanisms of the different responses of patients with CHC and AHC to pegIFN-alpha therapy. METHODS: We analyzed IFN signaling and ISG expression in liver samples from patients with AHC, patients with CHC, and individuals without hepatitis C (controls) using microarray, immunohistochemical, and protein analyses. Findings were compared with those from primary human hepatocytes stimulated with IFN-alpha or IFN-gamma, as reference sets. RESULTS: Expression levels of hundreds of genes, primarily those regulated by IFN-gamma, were altered in liver samples from patients with AHC compared with controls. Expression of IFN-gamma-stimulated genes was induced in liver samples from patients with AHC, whereas expression of IFN-alpha-stimulated genes was induced in samples from patients with CHC. In an expression analysis of negative regulators of IFN-alpha signaling, we did not observe differences in expression of suppresor of cytokine signaling 1 or SOCS3 between liver samples from patients with AHC and those with CHC. However, USP18 (another negative regulator of IFN-alpha signaling), was up-regulated in liver samples of patients with CHC that did not respond to therapy, but not in AHC. CONCLUSIONS: Differences in expression of ISGs might account for the greater response of patients with AHC, compared with those with CHC, to treatment with pegIFN-alpha and ribavirin. Specifically, USP18 is up-regulated in liver samples of patients with CHC that did not respond to therapy, but not in patients with AHC.

Consulter en ligne

Suggestions

Du même auteur

Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha

Archive ouverte | Lupberger, Joachim | CCSD

Interferon-alpha (IFN-alpha) exhibits its antiviral activity through signal transducer and activator of transcription protein (STAT) signaling and the expression of IFN response genes (IRGs). Viral infection has been shown to resu...

Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody

Archive ouverte | Mailly, Laurent | CCSD

International audience. Hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and cancer. Cell entry of HCV and other pathogens is mediated by tight junction (TJ) proteins, but successful therapeut...

IFN-lambda receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-lambda3 genotype and with nonresponsiveness to IFN-alpha therapies

Archive ouverte | Duong, F | CCSD

The molecular mechanisms that link IFN-lambda3 genotypes to differential induction of interferon (IFN)-stimulated genes (ISGs) in the liver of patients with chronic hepatitis C (CHC) are not known. We measured the expression of IF...

Chargement des enrichissements...